Adicet Bio, Inc. Common Stock ACET
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T05:11:21.148Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-04-16
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:03.294383642Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T05:02:29.919011+00:00
Adicet Bio, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.84 | 263.2% | 60.6% | |||
| 25Δ | 3.24 | 250.8% | 55.6% | |||
| 30Δ | 3.64 | 238.3% | 50.6% | |||
| 35Δ | 4.04 | 225.9% | 45.6% | |||
| 40Δ | 17.28 | 252.7% | 501.6% | 4.44 | 213.4% | 40.5% |
| 45Δ | 16.96 | 273.3% | 496.3% | 4.84 | 201.0% | 35.5% |
| 50Δ | 16.64 | 293.9% | 490.9% | 5.24 | 188.5% | 30.5% |
| 55Δ | 16.32 | 314.5% | 485.5% | 5.64 | 176.1% | 25.5% |
| 60Δ | 16.00 | 335.1% | 480.2% | 6.04 | 163.6% | 20.5% |
| 65Δ | 15.68 | 355.7% | 474.8% | 6.44 | 151.2% | 15.4% |
| 70Δ | 15.35 | 376.3% | 469.5% | 6.84 | 138.7% | 10.4% |
| 75Δ | 15.03 | 396.9% | 464.1% | 7.24 | 126.3% | 5.4% |
| 80Δ | 5.73 | 339.4% | 156.5% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.84
- IV
- 263.2%
- B/E move
- 60.6%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.24
- IV
- 250.8%
- B/E move
- 55.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.64
- IV
- 238.3%
- B/E move
- 50.6%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.04
- IV
- 225.9%
- B/E move
- 45.6%
40Δ
- Pseudo strike
- 17.28
- IV
- 252.7%
- B/E move
- 501.6%
- Pseudo strike
- 4.44
- IV
- 213.4%
- B/E move
- 40.5%
45Δ
- Pseudo strike
- 16.96
- IV
- 273.3%
- B/E move
- 496.3%
- Pseudo strike
- 4.84
- IV
- 201.0%
- B/E move
- 35.5%
50Δ
- Pseudo strike
- 16.64
- IV
- 293.9%
- B/E move
- 490.9%
- Pseudo strike
- 5.24
- IV
- 188.5%
- B/E move
- 30.5%
55Δ
- Pseudo strike
- 16.32
- IV
- 314.5%
- B/E move
- 485.5%
- Pseudo strike
- 5.64
- IV
- 176.1%
- B/E move
- 25.5%
60Δ
- Pseudo strike
- 16.00
- IV
- 335.1%
- B/E move
- 480.2%
- Pseudo strike
- 6.04
- IV
- 163.6%
- B/E move
- 20.5%
65Δ
- Pseudo strike
- 15.68
- IV
- 355.7%
- B/E move
- 474.8%
- Pseudo strike
- 6.44
- IV
- 151.2%
- B/E move
- 15.4%
70Δ
- Pseudo strike
- 15.35
- IV
- 376.3%
- B/E move
- 469.5%
- Pseudo strike
- 6.84
- IV
- 138.7%
- B/E move
- 10.4%
75Δ
- Pseudo strike
- 15.03
- IV
- 396.9%
- B/E move
- 464.1%
- Pseudo strike
- 7.24
- IV
- 126.3%
- B/E move
- 5.4%
80Δ
- Pseudo strike
- 5.73
- IV
- 339.4%
- B/E move
- 156.5%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 258.08% | |
| 165.59% | |
| 184.86% | |
| 167.61% | |
| 181.88% | |
| 249.35% | |
| 266.48% | |
| 161.86% | |
| 169.79% | |
| 165.17% | |
| 212.73% |
Biotechnology
ACHV
Description unavailable
More →ACIU
AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative…
More →ACOG
Description unavailable
More →ACRS
Description unavailable
More →ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and…
More →AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in…
More →